CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
Activating KRAS mutations are found in approximately 20% of human cancers but no RAS-directed therapies are currently available. Here we describe a novel, robust, KRAS synthetic lethal interaction with the cyclin dependent kinase, CDK1. This was discovered using parallel siRNA screens in KRAS mutant...
Saved in:
| Main Authors: | Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J Lord, Alan Ashworth |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0149099 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
NLK is a novel therapeutic target for PTEN deficient tumour cells.
by: Ana M Mendes-Pereira, et al.
Published: (2012-01-01) -
Computational screening of phytochemicals targeting mutant KRAS in colorectal cancer
by: Muskan Arooj, et al.
Published: (2025-08-01) -
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers
by: Roman M. Chabanon, et al.
Published: (2025-07-01) -
Modulating autophagy in KRAS mutant colorectal cancer using combination of oncolytic reovirus and carbamazepine.
by: Aaron Shaykevich, et al.
Published: (2025-01-01) -
Modulating autophagy in KRAS mutant colorectal cancer using combination of oncolytic reovirus and carbamazepine
by: Aaron Shaykevich, et al.
Published: (2025-01-01)